

# Valeant Pharmaceuticals Provides Update On Canadian Regulatory Filing About Future Financing Plans

September 27, 2017

LAVAL, Quebec, Sept. 27, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant" or the "Company") routinely evaluates refinancing opportunities, including capital markets transactions, to continue to enhance its capital structure. As part of this, the Company filed a routine private placement exemption application with Autorité des marchés financiers, the principal securities regulator in Quebec. At this time, no decision has been made with respect to any capital markets transactions. The Company does not intend to provide any updates on its financing plans until a definitive decision on any such financing has been made.

## About Valeant

Valeant Pharmaceuticals International, Inc. (NYSE/TSX:VRX) is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics. More information about Valeant can be found at [www.valeant.com](http://www.valeant.com).

## Forward-looking Statements

This press release may contain forward-looking statements which may generally be identified by the use of the words "anticipates," "expects," "intends," "plans," "should," "could," "would," "may," "will," "believes," "estimates," "potential," "target," or "continue" and variations or similar expressions. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties discussed in the Company's most recent annual or quarterly report and detailed from time to time in Valeant's other filings with the Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference. Readers are cautioned not to place undue reliance on any of these forward-looking statements. These forward-looking statements speak only as of the date hereof. Valeant undertakes no obligation to update any of these forward-looking statements to reflect events or circumstances after the date of this press release or to reflect actual outcomes, unless required by law.

### Investor Contact:

Arthur Shannon

[arthur.shannon@valeant.com](mailto:arthur.shannon@valeant.com)

### Media Contact:

Lainie Keller

[lainie.keller@valeant.com](mailto:lainie.keller@valeant.com)

(514) 856-3855

(908) 927-0617

(877) 281-6642 (toll free)

View original content with multimedia:

<http://www.prnewswire.com/news-releases/valeant-pharmaceuticals-provides-update-on-canadian-regulatory-filing-about-future-financing-plans-300527239.html>

SOURCE Valeant Pharmaceuticals International, Inc.



### Investor Inquiries

[ir@bauschhealth.com](mailto:ir@bauschhealth.com)

877-281-6642

514-856-3855 (Canada)

### Media inquiries

[Corporate.communications@bauschhealth.com](mailto:Corporate.communications@bauschhealth.com)

908-569-3692

[LEGAL NOTICE](#)

[PRIVACY POLICY](#)

[EMAIL ALERTS](#)

[EMAIL PAGE](#)

[RSS FEED](#)

Use of this site signifies your agreement to the Legal Notice and Privacy Policy.

©2026 Bausch Health Companies Inc. All rights reserved. MTB.0230.USA.18 V2.0

**CALIFORNIA RESIDENTS: DO NOT SELL MY PERSONAL INFORMATION**